Our business strategy involves transforming our research into clinically meaningful products. The primary motivation is to discover 'disease-modifying medicines' while the enterprise is financially sustainable. To achieve our objective, we actively seek partnerships, licensing agreements, and strategic alliances with the pharmaceutical and biotech industries worldwide. We out-license our products (considering the novel mechanism of action, clinical efficacy, and safety) to continuously support Hado's finances and reputation. Our collaborators and partners can benefit from using Hado's approaches to drug discovery as a supporting tool to bring the best possible medicines. Partners in the pharmaceutical industry are welcome to develop first-in-class therapies for global patients using Hado's lead candidates, typically under collaborative arrangements.